The Lancet Refuses Senate Request on COVID-19 Origins Inquiry
The Lancet refused a U.S. Senate request for evidence on COVID-19 origins. Purdue Pharma's sentencing was delayed, while insurers moved to reduce prior-authorization paperwork.
The Lancet has refused a request by the U.S. Senate to provide evidence regarding the origins of COVID-19, according to editor-in-chief Richard Horton. He confirmed the decision in an interview at the Reuters Pharma event. This article summarizes current health news, including Purdue Pharma's delayed sentencing over opioid charges, initiatives by health insurers to streamline prior authorization, and the FDA's expedited drug program.
Purdue Pharma's sentencing over opioid marketing charges has been postponed. A federal judge delayed the proceedings to allow more public involvement before accepting the company's guilty plea and imposing fines totaling $5.5 billion.
Efforts to standardize health insurance processes are gaining momentum with UnitedHealth and CVS Health reducing paperwork for prior authorizations. These developments are part of broader industry commitments to enhance transparency and efficiency.